BELLUS Health Inc.

NasdaqGS:BLU Aktierapport

Börsvärde: US$1.9b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

BELLUS Health Utdelningar och återköp

Utdelning kriterier kontrolleras 0/6

BELLUS Health har inte registrerat sig för att betala utdelning.

Viktig information

n/a

Avkastning på utdelning

-9.4%

Återköpsavkastning

Total avkastning till aktieägarna-9.4%
Framtida utdelningsavkastningn/a
Utdelningstillväxtn/a
Nästa utbetalningsdag för utdelningn/a
Ex utdelningsdagn/a
Utdelning per aktien/a
Utdelningsandeln/a

Senaste utdelnings- och återköpsuppdateringar

Inga uppdateringar

Recent updates

Seeking Alpha • Sep 07

Bellus: Expected Phase 3 Start Makes This A Long-Term Play

Summary BELLUS Health intends to initiate two phase 3 studies in Q4 of 2022; these will be CALM-1 and CALM-2 studies using BLU-5937 for treatment of patients with refractory chronic cough. Final results from the phase 3 CALM-1 and CALM-2 studies using BLU-5937 for treatment of patients with refractory chronic cough are expected 2nd half of 2024. Initiation of a phase 1 study using a once-daily extended release formulation of BLU-5937 for refractory chronic cough is expected in Q4 of 2022. BELLUS has pro forma cash of $384.6 million, which it believes is enough to fund its operations into the 2nd half of 2025. BELLUS Health Inc. (BLU) is a great long-term biotech play to look into. The reason why I state that is because it intends to initiate two phase 3 studies in Q4 of 2022 known as CALM-1 and CALM-2. It will be using its drug BLU-5937 for the treatment of patients with refractory chronic cough ((RCC)). The reason why it is able to advance this program is because of a positive end-of-phase 2 meeting with the FDA. Investors may have to wait a bit to see the final results of the phase 3 studies, because final results won't be released until the 2nd half of 2024. However, the company just raised additional cash in July 2022, and it believes it has enough to fund its operations into the 2nd half of 2025. This should be enough to carry it through the data readouts from both of the CALM-1 and CALM-2 studies. Even better, the use of the CALM program can be used for potential approval in the U.S. and the European Union. With so much time until the results, it might even be prudent to wait and see two conditions before buying in. First, the market conditions don't worsen, especially with already two negative quarters of GDP. Plus, the fact that even though it states it has enough cash until then, I believe it may need to raise additional cash again at least once before it runs out in 2025. This may give one an entry point if they intend to wait and see if the stock does pull back a bit, because of these two conditions. Still, looking at it from a long-term perspective, I believe that this offers significant value. Success With End-Of-Phase 2 Meeting Brings Advancement To Phase 3 BELLUS Health has already completed a successful end of phase 2 meeting with the FDA recently for the use of BLU-5937 for the treatment of patients with refractory chronic cough ((RCC)). Not only that but it has already received guidance from the European Medicines Agency ((EMA)) as well. With both of these steps having been done, it has decided how it will design both of its CALM-1 and CALM-2 studies. Both of these phase 3 studies are going to be using BLU-5937 for the treatment of patients with RCC and will be initiated in Q4 of 2022. I believe that the launching of these studies may act as a catalyst for the stock. Not as much as when clinical results are released but the stock may react to such news. A chronic cough is a type of cough that lasts for 8 weeks or more in adults and then roughly about 4 weeks in children. Consider that this type of disease is not just a hassle to deal with, but also that it may cause substantial health problems. Such health problems these patients have to go through: Interruption of sleep Feeling exhausted and out of breath Vomiting after excessive cough Feeling lightheaded Rib fractures occurring It is a large market and if BELLUS can find a way to help these patients experience relief it could make a lot of revenues. The global chronic cough market is expected to reach $9.85 billion by 2027. This is a pretty good amount of potential revenue for a first indication for it. The phase 3 studies will consist of a primary endpoint dealing with 24-hour cough frequency measured at 12 and 24 weeks. How will cough frequency be counted for this study to be adequate? Well, there will be the use of VitaloJAK cough monitoring system. It has been a device used in research since 2005 and in phase 2/phase 3 studies globally since 2014. The reason why BELLUS Health got the meeting that it did with the FDA and talks with the EMA, is because of the positive results it achieved in the phase 2b SOOTHE study that was completed. In this study, it achieved statistical significance of the primary endpoint having achieved 34% placebo-adjusted reduction in 24-hour cough frequency observed with a p-value of p ≤ 0.005 at day 28. Not only did it achieve the primary endpoint for this study, but it did so with low rates of taste-related adverse events with all doses. The percentage of taste-related adverse events was ≤6.5%. There is another small catalyst expected in Q4 of 2022. This involves the initiation of a phase 1 study which will look at once-daily extended release formulation of BLU-5937. It remains to be seen if this extended release formulation will do better, but it does give the biotech a chance at expanding its potential in treating patients with refractory chronic cough. Financials According to the 6-K SEC Filing, BELLUS Health had cash, cash equivalents and short-term investments totaling $220.1 million as of June 30, 2022. However, as I stated in the beginning above, it was able to raise cash in July 2022 with an offering. It enacted an offering of its common shares, resulting in the net proceeds of $176 million, including the full exercise of the over-allotment option. Thus, including the recent July 2022 cash raise, it has pro forma cash of $384.6 million. Based on the cash on hand, it believes it can fund its operations to the 2nd half of 2025. This might be enough to carry it through the data readouts of both phase 3 CALM studies, which are expected in the 2nd half of 2024. As I stated above, I believe that it may need to raise cash again before the expected data readouts. While I don't believe it will be done early, I think it may need to raise cash again at least by the end of 2024/early 2025 as my estimate. The only way it would need to raise cash earlier than expected is if it enacts another strategic transaction that is not yet known. Other than that, I think it does have enough cash for a few years. Risks To Business
Seeking Alpha • Jul 12

BELLUS details late-stage plans for cough candidate after FDA meeting

Following an End-of-Phase 2 with the FDA, Canadian biotech BELLUS Health (NASDAQ:BLU) announced plans to conduct two pivotal trials as part of its Phase 3 development for lead candidate BLU-5937 in refractory chronic cough (“RCC”). The CALM-1 and CALM-2 studies will be designed to evaluate the efficacy, safety and tolerability of BLU-5937 in nearly 675 adult patients. The company plans to enroll the first patient in 4Q 2022 for the two placebo-controlled studies, which will run parallelly testing 25 mg BID, 50 mg BID doses of BLU-5937. The primary endpoints of CALM-1 and CALM-2 are 24H cough frequency measured at 12-weeks and 24-weeks, respectively. Topline data from CALM-1 are expected in 2H 2024. Read: Bellus (BLU) shares climbed in December after the company announced favorable mid-stage data for BLU-5937 in RCC.
Seeking Alpha • Dec 14

BELLUS Proof Of Data In Chronic Cough Using BLU-5937 Brings Hope To Patients

BELLUS achieved primary endpoint of phase 2b SOOTHE study using BLU-5937 in patients with refractory chronic cough. An end of phase 2b meeting with the FDA for BLU-5937 in refractory chronic cough is expected in Q2 of 2022, with phase 3 study likely to start in 2nd half of 2022. The global chronic cough market is expected to reach $9.85 billion by 2027. Merck, Bayer AG and others have similar types of P2X3 drugs, but BELLUS may possibly have an advantage on tolerability/taste alterations profile.
Seeking Alpha • Aug 27

Bellus Health - Betting Big On Chronic Cough Treatment

Bellus’ lead drug candidate, BLU-5937, has the potential to capture significant market share if the drug attains commercialization. Bellus has adequate cash on its books, lasting until at least the duration of 2022. The company has no long-term debt. Bellus claims 100% ownership of the intellectual property rights for both BLU-5937 and related P2X3 antagonists. Assuming a base case revenue of $320 million in the year 2028 and a P/S ratio of 6.0x, the company’s intrinsic value comes out to be $774 million or $9.80 per share, indicating an upside close to 3x.

Stabilitet och tillväxt i betalningar

Hämta utdelningsdata

Stabil utdelning: Otillräcklig data för att avgöra om BLU s utdelningar per aktie har varit stabila tidigare.

Växande utdelning: Otillräcklig data för att avgöra om BLU s utdelningsbetalningar har ökat.

Utdelningsavkastning jämfört med marknaden

BELLUS Health Utdelningsavkastning jämfört med marknaden
Hur är BLU:s direktavkastning jämfört med marknaden?
SegmentUtdelningsavkastning
Företag (BLU)n/a
Marknadens lägsta 25% (US)1.3%
Marknad Topp 25% (US)4.0%
Genomsnitt för branschen (Biotechs)1.9%
Prognosanalytiker (BLU) (upp till 3 år)n/a

Anmärkningsvärd utdelning: Det går inte att utvärdera BLU s utdelningsavkastning mot de lägsta 25 % av utdelningsbetalarna, eftersom företaget inte har rapporterat några senaste utbetalningar.

Hög utdelning: Det går inte att utvärdera BLU s utdelningsavkastning mot de översta 25 % av utdelningsbetalarna, eftersom företaget inte har rapporterat några senaste utbetalningar.

Vinstutdelning till aktieägarna

Resultattäckning: Otillräcklig data för att beräkna BLU s utbetalningskvot för att avgöra om dess utdelningar täcks av intäkter.

Kontantutbetalning till aktieägarna

Kassaflödestäckning: Det går inte att beräkna hållbarheten för utdelningar eftersom BLU inte har rapporterat några utbetalningar.

Upptäck bolag med stark utdelning

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2023/06/28 19:26
Aktiekurs vid dagens slut2023/06/28 00:00
Intäkter2023/03/31
Årlig intjäning2022/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

BELLUS Health Inc. bevakas av 11 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Brian SkorneyBaird
Justin ZelinBTIG
Pooya HemamiEdison Investment Research